期刊文献+

半乳糖基壳聚糖/5-氟尿嘧啶纳米粒抑制小鼠原位肝癌移植模型的实验研究 被引量:1

Galactosylated Chitosan/5-fluorouracil Nanoparticles Inhibit Hepatocellular Carcinoma in the Orthotopic Transplant Mouse Model
原文传递
导出
摘要 目的:观察半乳糖基壳聚糖(GC)/5-氟尿嘧啶(5-FU)纳米粒抑制小鼠原位肝癌移植模型的疗效及机制。方法:合成GC/5-FU纳米粒,建立小鼠原位肝癌移植模型,通过动物实验观察GC/5-FU纳米粒治疗小鼠原位肝癌移植模型的疗效,通过原位末端标记法(TUNEL法)检测肝癌的凋亡。结果:GC/5-FU纳米粒成功合成,呈规则的球形,表面光滑,大小均匀,纳米粒间无粘连。实验结束时,小鼠的肝癌组织称重,进行方差分析发现GC/5-Fu的瘤重为(0.4361±0.1153)g,5-Fu组为(0.7932±0.1283)g,GC为(1.3989±0.2125)g,和对照组为(1.5801±0.2821)g,4组瘤重之间差异有显著的统计学意义(P<0.01)。GC/5-FU组和5-FU组的瘤重明显小于GC组及对照组,差异有统学意义(P<0.01);GC/5-FU的瘤重又显著小于5-Fu组(P<0.01)。观察各组小鼠的生存期发现对照组的中位生存时间为12d,GC组为13d,5-FU为17d,而GC/5-FU组最高为30d。GC/5-FU组的生存时间最长。通过TUNEL法观察肝癌细胞的凋亡发现GC/5-FU组的平均凋亡指数(AI)为21.34%较5-FU组的14.74%明显增高(P<0.05),均较GC组和对照组明显增高,而GC组和对照组间的AI无明显差异(P>0.05)。结论:GC/5-FU纳米粒在体内对小鼠原位肝癌具有明显抑制作用,较5-FU明显增强。其机理可能与GC能通过细胞膜将5-FU从细胞外转移到细胞内,增强5-FU对肝癌细胞的凋亡。 Objective: To observe the efficacy and mechanism of hepatocellular carcinoma in the orthotopic transplant mouse model with galactosylated chitosan(GC) / 5-fluorouracil(5-FU) nanoparticles.Methods: The GC/5-FU nanoparticles were prepared,the hepatocellular carcinoma in the orthotopic transplant mouse model were established,the apoptosis in liver cancer by TdT-mediated dUTP nick end labeling(TUNEL) were detected.Results: GC/5-FU nanoparticles were successfully synthesized in spherical,smooth surface,uniform size,no adhesion between the nanoparticles.At the end of the experiment,the weight of the tumor in each group was: 0.4361± 0.1153 g in GC/5-FU group,0.7932±0.1283 g in 5-FU group,1.3989±0.2125 g in GC group and 1.5801±0.2821 g in control group.The differences between the groups was statistically significant(P0.01).The tumor weight in the GC/5-FU group and the 5-FU were significantly less than those in the GC group and control group(P0.01);tumors in the GC/5-FU group were significantly less compared with the 5-FU group(P0.01).The median survival for control,GC,5-FU and GC/5-FU groups were 12 d,13 d,17 d,and 30 d,respectively.The longest median survival time was seen in the GC/5-FU group(P0.01).Quantification of the apoptosis index(AI) identified a statistically significant difference between the GC/5-FU group(AI = 21.34%) and the 5-FU group(AI = 14.74%,P0.05),both of which were higher than that in the GC and control groups(P0.01).Conclusion: GC/5-FU nanoparticles can also significantly inhibit the tumor growth in the orthotropic liver cancer mouse model,and this in vivo effect is stronger than that of 5-FU alone.GC facilitates intracellular transport of 5-FU,and increases the apoptosis of liver cancer induced by 5-FU.
出处 《现代生物医学进展》 CAS 2012年第35期6819-6823,共5页 Progress in Modern Biomedicine
基金 上海市自然科学基金项目(09ZR1424700 114119a4700) 闵行区卫生局科学基金项目(2009MW28)
关键词 半乳糖基壳聚糖 纳米粒 5-氟尿嘧啶 肝癌 凋亡 Galactosylated chitosan Nanoparticles 5-fluorouracil Liver cancer Apoptosis
  • 相关文献

参考文献20

  • 1Rougier P,Lepere C. Second-line treatment of patients with metastatic colorectal cancer[J].Seminars in Oncology,2005,(6 Suppl 9):S48-S54. 被引量:1
  • 2Lievre A,Samalin E,Mitry E. Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer:a retrospective study[J].BMC Cancer,2009.347. 被引量:1
  • 3Thomas A M,Kapanen A I,Hare J I. Development of a liposomal nanoparticle formulation of 5-fluorouracil for parenteral administration:formulation design,pharmacokinetics and efficacy[J].Journal of Controlled Release,2011,(02):212-219. 被引量:1
  • 4Robidoux A,Buzdar A U,Quinaux E. A phase II neoadjuvant trial of sequential nanoparticle albumin-bound paclitaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide in locally advanced breast cancer[J].Clinical Breast Cancer,2010,(01):81-86. 被引量:1
  • 5Beumer J H,Boisdron-Celle M,Clarke W. Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer[J].Therapeutic Drug Monitoring,2009,(06):688-694. 被引量:1
  • 6Cheng M,Li Q,Wan T. Synthesis and efficient hepatocyte targeting of galactosylated chitosan as a gene carrier in vitro and in vivo[J].Journal of Biomedical Materials Research Part B:Applied Biomaterials,2011,(01):70-80. 被引量:1
  • 7Li D C,Zhong X K,Zeng Z P. Application of targeted drug delivery system in Chinese medicine[J].Journal of Controlled Release,2009,(02):103-112.doi:10.1016/j.jconrel.2009.05.008. 被引量:1
  • 8Whitesides G M. The 'right' size in nanobiotechnology[J].Nature Biotechnology,2003,(10):1161-1165.doi:10.1038/nbt872. 被引量:1
  • 9Marcucci F,Lefoulon F. Active targeting with particulate drug carriers in tumor therapy:fundamentals and recent progress[J].Drug Discovery Today,2004,(05):219-228.doi:10.1016/S1359-6446(03)02988-X. 被引量:1
  • 10Alex S M,Rekha M R,Sharma C P. Spermine grafted galactosylated chitosan for improved nanoparticle mediated gene delivery[J].International Journal of Pharmaceutics,2011,(1-2):125-137. 被引量:1

同被引文献14

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部